Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brilinta Review Highlights Evidence Gap On Aspirin Dosing

Executive Summary

The right aspirin dose is a looming unknown in dual antiplatelet therapy. However, unless the National Institutes of Health or another entity steps in to run a large, expensive study, it appears likely the question will remain unanswered

You may also be interested in...



Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta

AstraZeneca could face a significant commercial challenge for its antiplatelet agent Brilinta (ticagrelor) if, as expected, FDA approves the drug with a recommendation for concomitant use of low-dose aspirin in acute coronary syndrome patients

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel